Registry-listed formulations

Minzasolmin · chembl:CHEMBL5095072

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 2 studies. This list may not include all unresolved or historical entries.

  • Minzasolmin (UCB0599)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • UCB0599 PRD4385815Registry product

    Named ingredient; product remains distinct

    Formulation reported by source: CAPSULE, HARD

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • MinzasolminRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: FILM-COATED TABLET

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • UCB0599 PRD4385815Registry product

    Named ingredient; product remains distinct

    Formulation reported by source: CAPSULE, HARD

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(50%)

Phase Distribution

Phase 1
1
50%
Phase 2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

Clinical Trials (2)

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
2

External References

Names & Codes

Research Codes

DLX-313UCB-0599